NMN and NMNH are related compounds, but the extra H identifies a different chemical form. Research or sales claims about one should not be treated as interchangeable evidence for the other.
NMNH is often promoted using large NAD-increase claims. Before comparing those numbers with a human NMN study, identify whether the experiment involved cells, animals, or people and how the ingredient was delivered.
NMNH requires its own evidence. A laboratory increase in NAD and a completed trial registration do not establish superior clinical benefits for a retail product.
What does the extra H mean?
NMNH is the reduced form of nicotinamide mononucleotide. Related names do not make identical interventions: the compounds can differ in how they are handled and studied. The same naming issue occurs with NAD and NADH. Avoid using a shared part of the name as a reason to substitute one product or research result for another.
Where do the large potency claims come from?
A 2021 NMNH paper examined cells and mice and reported strong effects on NAD-related metabolism. That is preclinical evidence. It cannot show how much a person should take, whether a retail capsule produces the same response, or whether a larger biomarker change improves health. A multiple from one experiment is not a universal human potency ratio.
Has NMNH entered human research?
Yes. NCT06889740 describes a randomized, blinded, placebo-controlled NMNH study with 80 participants. The record was marked completed, but no results section was posted in the registry when checked. This supports saying that human research has been registered and completed according to the record; it does not support declaring that the trial proved safety or benefit.
Why registration is not a positive result
A trial registry describes a plan and reported study status. To judge findings, look for the actual results, losses to follow-up, adverse events, comparisons, and publication. A completed status alone does not reveal whether the main endpoint succeeded. Our research-reading guide explains why a sales page linking a trial identifier has not necessarily supplied clinical evidence.
What about formulas that contain both?
Some current ProHealth Triple Boost formulations list NMNH alongside another precursor. That makes the whole formula a separate question from an NMN-only trial. Adding the ingredient weights together does not produce an equivalent amount of absorbed NAD. Ask which study tested the complete combination at the same amounts and duration.
A practical way to compare offers
Record the exact chemical name, ingredient amount per full serving, other ingredients, and the kind of evidence cited. If the main attraction is a claim of being many times stronger, ask what was measured and in whom. Use the NMN shortlist for established product identities and quality-testing guidance for batch documentation; neither substitutes for clinical evidence.
Sources & reading notes
Editorial source review updated September 18, 2026. Provider pages describe their own offers; inclusion does not verify a product or its results.
- NMNH as an NAD precursor in mammalian cells and mice (2021) Preclinical research; cannot establish clinical benefit or long-term safety of a retail human formulation.
- ClinicalTrials.gov: UthPeak NMNH trial NCT06889740 Registry and official API checked: completed, 80 participants, no results section posted at the time of review. Registration is not a favorable trial result. Checked September 18, 2026.
- ProHealth: NAD Triple Boost with NMN Manufacturer NMN formulation panel, revision 06.25; lists NMN, NMNH, and other ingredients, distinct from the NR version.
- Yoshino et al. (2021): NMN and muscle insulin sensitivity Small randomized study in postmenopausal women with prediabetes; not evidence for NAD injections or general weight loss.
- FDA: questions and answers on dietary supplements Regulatory categories and limits of premarket review.
Educational information, not individualized medical advice. We do not claim medical review or firsthand treatment experience. Read our review standards and commercial disclosure.